default author photo

Suellen Nicholson

Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity

SCHOLARLY PAPERS

3

DOWNLOADS

640

TOTAL CITATIONS

3

Scholarly Papers (3)

1.

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

Number of pages: 37 Posted: 01 Feb 2021
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland, University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Queensland - TetraQ, University of Queensland - TetraQ, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Burnet Institute, Burnet Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 414 (176,035)
Citation 2

Abstract:

Loading...

2.

The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old

Number of pages: 39 Posted: 08 Jul 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 116 (613,149)
Citation 1

Abstract:

Loading...

COVID-19, Booster Vaccines, Immunogenicity, adaptive platform trial, health policy.

3.

The Platform Trial in COVID-19 Priming and Boosting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Different COVID-19 Vaccinations Administered as a Second Booster (Fourth Dose) in Azd1222 Primed Individuals Aged 50-<70 Years Old

Number of pages: 13 Posted: 07 May 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 110 (640,165)

Abstract:

Loading...

Adaptive platform trial, COVID-19, vaccines, Bayesian, immunisation, policy